Urothelial carcinoma

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

Researchers at Dana-Farber Cancer Institute are testing whether information from a bladder tumor's genes, combined with how the tumor responds to chemotherapy, can help doctors and patients decide between bladder-sparing chemoradiation and surgery to remove the bladder. The study…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This study tests a targeted cancer drug called erdafitinib, alone or combined with an immunotherapy (cetrelimab) and/or chemotherapy, in 125 people with advanced urothelial cancer that has spread. The goal is to find safe doses and see if the treatments shrink tumors. Participant…

This phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This early-phase study tested a new drug called UGN-201 in 10 people with bladder cancer who were scheduled to have their bladder removed. The main goal was to check the drug's safety and see if it caused any serious side effects or surgery delays. Researchers also looked for sig…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study tests if the drug enfortumab vedotin can safely and effectively shrink or eliminate high-grade urothelial carcinoma in the upper urinary tract before standard surgery. It includes 24 people who cannot take or choose not to take the chemotherapy drug cisplatin. The main…

This phase 3 study tests whether a combination of disitamab vedotin and pembrolizumab works better than standard chemotherapy for people with advanced bladder cancer that has spread. The cancer must have a protein called HER2. About 412 participants will be randomly assigned to e…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and preve…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab plus chemo or a placebo…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…

This early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This phase 2 trial is testing whether the immunotherapy drug Keytruda (pembrolizumab) can help people with muscle-invasive bladder cancer avoid having their bladder removed. About 46 participants will receive two cycles of Keytruda, then doctors will check if the cancer has compl…

This study looks at adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) for people with advanced or metastatic bladder cancer that cannot be removed by surgery. Researchers want to see if giving the drugs in a different order—chemothera…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…

This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…

This early-phase trial tests whether combining two drugs—avelumab (an immunotherapy) and AVB-S6-500 (a targeted therapy)—is safe and can help people with advanced bladder cancer that has worsened after chemotherapy. Nineteen adults with inoperable or metastatic urothelial carcino…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and works better for people with advanced bladder cancer. About 54 participants will receive the combination treatment. The goal is to see if the combo…

This early-stage trial tests a new way to treat high-grade bladder cancer that hasn't spread into the muscle. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the bladder. The goal is to see if this is safe and can shrink or elimi…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…

This early-phase study tests a new oral drug, ABSK121-NX, in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check safety and find the right dose. About 169 adults will take part, and researchers will also look for any signs th…

This study is testing a simple urine test called CxBladder to see if it can accurately detect when bladder cancer comes back. Currently, patients need a camera inserted into the bladder (cystoscopy) for monitoring, which is uncomfortable and costly. The study will collect urine s…

This study is testing a new, non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have microscopic blood in their urine. Currently, these patients often need a cystoscopy, an invasive procedure where a camera is inse…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study compares two imaging techniques—CT urography (CTU) and intravenous urography (IVU)—in 133 bladder cancer patients to see if CTU alone can effectively monitor the disease. Researchers want to determine if CTU provides clear enough images of the urinary tract to replace …

This study compares two CT urography methods for diagnosing urothelial carcinoma (a type of urinary tract cancer). 352 adults with blood in urine or a history of this cancer will be randomly assigned to receive either a single-bolus or split-bolus CT scan. Researchers will compar…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…